Bronchopulmonary Dysplasia-Pipeline Review, H1 2016

Bronchopulmonary Dysplasia-Pipeline Review, H1 2016

  • Products Id :- GMDHC7758IDB
  • |
  • Pages: 63
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary


Global Markets Direct's, 'Bronchopulmonary Dysplasia-Pipeline Review, H1 2016', provides an overview of the Bronchopulmonary Dysplasia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia

The report reviews pipeline therapeutics for Bronchopulmonary Dysplasia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bronchopulmonary Dysplasia therapeutics and enlists all their major and minor projects

The report assesses Bronchopulmonary Dysplasia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bronchopulmonary Dysplasia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Bronchopulmonary Dysplasia Overview 7

Therapeutics Development 8

Pipeline Products for Bronchopulmonary Dysplasia-Overview 8

Bronchopulmonary Dysplasia-Therapeutics under Development by Companies 9

Bronchopulmonary Dysplasia-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Bronchopulmonary Dysplasia-Products under Development by Companies 13

Bronchopulmonary Dysplasia-Companies Involved in Therapeutics Development 14

Airway Therapeutics, Inc. 14

AstraZeneca Plc 15

Chiesi Farmaceutici SpA 16

MediPost Co., Ltd. 17

Syntrix Biosystems, Inc. 18

Therabron Therapeutics, Inc. 19

Bronchopulmonary Dysplasia-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

AT-100-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

budesonide-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

CG-100-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Drugs for Bronchopulmonary Dysplasia-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

gefitinib-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Pneumostem-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

R-190-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

R-801-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

R-901-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

R-908-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

SX-576-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Bronchopulmonary Dysplasia-Recent Pipeline Updates 52

Bronchopulmonary Dysplasia-Dormant Projects 54

Bronchopulmonary Dysplasia-Discontinued Products 55

Bronchopulmonary Dysplasia-Product Development Milestones 56

Featured News & Press Releases 56

Mar 02, 2016: Therabron Therapeutics Announces New Study Aimed at the Creation of Multiple Novel Isoforms of the Company Lead Product Candidate 56

Dec 08, 2015: Therabron Therapeutics Announces Favorable Infant Outcomes with Six-Month Follow-Up of a Phase 1b Recombinant Human CC10 Clinical Trial 56

Oct 20, 2015: Therabron Therapeutics Receives Notice of Allowance for New EU Patent Supporting its Recombinant CC10 Technology Platform 57

Jul 21, 2015: Therabron Therapeutics Reaches 50 Percent Enrollment in Phase 2 Clinical Trial for Lead Pediatric Respiratory Critical Care Program 57

May 13, 2015: Therabron Therapeutics Secures New Orphan Designation for the Prevention of Bronchopulmonary Dysplasia 58

Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung 58

Aug 12, 2014: MediPost, lung disease stem cell treatment drug 'Pneumostem' application for US clinical trial 59

Jul 29, 2014: Lung disease stem cell drug designated 'orphan drug in development stage' 59

Feb 06, 2014: Stem cells to treat lung disease in preterm infants 60

Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem 60

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Figures

Number of Products under Development for Bronchopulmonary Dysplasia, H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Comparative Analysis by Clinical Stage Development, H1 2016 11

Comparative Analysis by Early Stage Products, H1 2016 12

Assessment by Monotherapy Products, H1 2016 20

Number of Products by Targets, H1 2016 21

Number of Products by Stage and Targets, H1 2016 21

Number of Products by Mechanism of Actions, H1 2016 23

Number of Products by Stage and Mechanism of Actions, H1 2016 23

Number of Products by Routes of Administration, H1 2016 25

Number of Products by Stage and Routes of Administration, H1 2016 25

Number of Products by Molecule Types, H1 2016 27

Number of Products by Stage and Molecule Types, H1 2016 27

List of Tables

Number of Products under Development for Bronchopulmonary Dysplasia, H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Comparative Analysis by Late Stage Development, H1 2016 10

Comparative Analysis by Clinical Stage Development, H1 2016 11

Comparative Analysis by Early Stage Development, H1 2016 12

Products under Development by Companies, H1 2016 13

Bronchopulmonary Dysplasia-Pipeline by Airway Therapeutics, Inc., H1 2016 14

Bronchopulmonary Dysplasia-Pipeline by AstraZeneca Plc, H1 2016 15

Bronchopulmonary Dysplasia-Pipeline by Chiesi Farmaceutici SpA, H1 2016 16

Bronchopulmonary Dysplasia-Pipeline by MediPost Co., Ltd., H1 2016 17

Bronchopulmonary Dysplasia-Pipeline by Syntrix Biosystems, Inc., H1 2016 18

Bronchopulmonary Dysplasia-Pipeline by Therabron Therapeutics, Inc., H1 2016 19

Assessment by Monotherapy Products, H1 2016 20

Number of Products by Stage and Target, H1 2016 22

Number of Products by Stage and Mechanism of Action, H1 2016 24

Number of Products by Stage and Route of Administration, H1 2016 26

Number of Products by Stage and Molecule Type, H1 2016 28

Bronchopulmonary Dysplasia Therapeutics-Recent Pipeline Updates, H1 2016 52

Bronchopulmonary Dysplasia-Dormant Projects, H1 2016 54

Bronchopulmonary Dysplasia-Discontinued Products, H1 2016 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Airway Therapeutics, Inc.

AstraZeneca Plc

Chiesi Farmaceutici SpA

MediPost Co., Ltd.

Syntrix Biosystems, Inc.

Therabron Therapeutics, Inc.

Bronchopulmonary Dysplasia Therapeutic Products under Development, Key Players in Bronchopulmonary Dysplasia Therapeutics, Bronchopulmonary Dysplasia Pipeline Overview, Bronchopulmonary Dysplasia Pipeline, Bronchopulmonary Dysplasia Pipeline Assessment

select a license
Single User License
USD 2000 INR 146960
Site License
USD 4000 INR 293920
Corporate User License
USD 6000 INR 440880



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]